Thursday 28th September 2023 |
Text too small? |
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb today retired from the board following his announcement at the ASM that he would be stepping down once a new independent director had been appointed. This is in conjunction with today’s appointment of Andrew Lane to the Board.
Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service during his 11-year tenure. His deep industry knowledge and experience has enabled him to make a significant contribution to the growth and success of AFT, and it has been a privilege to work alongside him.”
Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals (ASX:AFP, NZX: AFT )
www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.
No comments yet
POT Financial Results for the year to 30 June 2025
MOVE FY25 Results for the year ended 30 June 2025
BPG - Completion of Retail Offer
Comvita releases results for the year ended 30 June 2025
August 29th Morning Report
Air New Zealand announces 2025 financial result
August 28th Morning Report
VSL - 2025 date of Annual Meeting of shareholders
WIN - Winton announces FY25 Annual Results
Meridian Energy Limited 2025 Full Year Financial Results